---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-089095"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2024-10-21T23:59:59+00:00"
generated_at: "2026-05-30T12:32:52.177737+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Kyverna Therapeutics appoints cell therapy veteran Mert Aktar to board

## Summary
- Appointed Mert Aktar as Class III director, effective Oct 20, 2024; joins Audit and Science & Technology Committees.
- Aktar currently CEO of Receptive Bio; previously SVP Global Head of Corp Dev at Kite Pharma; over 20 years biopharma experience.
- As non-employee director, receives $40k/yr cash, $10k Audit, $7.5k SciTech committee fees; plus $350k option grant vesting monthly over 3 years.
- Appointment adds cell therapy and corporate development expertise as Kyverna advances KYV-101 in autoimmune disease trials.

## SEC filing metadata
- accession: 0001213900-24-089095
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2024-10-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000121390024089095/0001213900-24-089095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000121390024089095/ea0218096-8k_kyverna.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-089095
- JSON: https://secwatch.observer/filing/0001213900-24-089095.json
- Plain text: https://secwatch.observer/filing/0001213900-24-089095.txt

## Key facts
- Executive change
  Mert Aktar was appointed as Class III director at Kyverna Therapeutics, Inc..
  - Action: appointed
  - Role: Class III director
  source text: On October 20, 2024, the board of directors (the "Board") of Kyverna Therapeutics, Inc. (the "Company") appointed Mert Aktar as a Class III director of the Company, effective October 20, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1994702/000121390024089095/0001213900-24-089095-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.